Table 1 A high score for suppression of tumor immunity associates with National Comprehensive Cancer Network (NCCN) Risk Score for metastatic prostate cancer.

From: Serum proteomics links suppression of tumor immunity to ancestry and lethal prostate cancer

NCCN risk score

Total OR (95% CI)a

AA OR (95% CI)

EA OR (95% CI)

Low

Ref.

Ref.

Ref.

Intermediate

1.04 (0.68–1.59)

0.89 (0.46–1.70)

1.18 (0.65, 2.13)

High/Very High

1.47 (0.87–2.48)

1.33 (0.59–2.98)

1.72 (0.83, 3.54)

Regional/Metastatic

3.79 (1.59–9.04)

5.90 (1.43–24.34)

3.16 (0.95, 10.50)

P value for trend

0.004

0.019

0.040

  1. Bolded data indicate significant associations in the logistic regression analysis.
  2. High suppression of tumor immunity is defined by the median score in the NCI-Maryland control population (>median vs. ≤median).
  3. aLogistic regression adjusted for age at study entry, BMI (kg/m2), diabetes (no/yes), aspirin (no/yes), education (high school or less, some college, college, professional school), family history of prostate cancer (first-degree relatives, yes/no), self-reported race (not included in the stratified analysis), income (<$10k, $10–30 K, $30–60 K, $60–90k, >$90k), smoking history (never, former, current), treatment (0 = none, 1 = surgery, 2 = radiation, 3 = hormone, 4 = combination).
Back to article page